<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042091</url>
  </required_header>
  <id_info>
    <org_study_id>16D.204</org_study_id>
    <nct_id>NCT03042091</nct_id>
  </id_info>
  <brief_title>Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery</brief_title>
  <official_title>Combined Mechanical and Oral Antibiotic Bowel Preparation Versus Oral Antibiotics Alone for the Reduction of Surgical Site Infection Following Elective Colorectal Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies how well neomycin and metronidazole hydrochloride with
      or without polyethylene glycol work in reducing infection in patients undergoing elective
      colorectal surgery. Polyethylene glycol, may draw water from the body into the colon,
      flushing out the contents of the colon. Antibiotics, like neomycin and metronidazole
      hydrochloride, may stop bacteria from growing. It is not yet known whether it's better to
      give preoperative neomycin and metronidazole hydrochloride with or without polyethylene
      glycol in reducing surgical site infection after colorectal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the difference in rates of surgical site infection following elective
      colorectal resections in patients given a preoperative mechanical bowel prep with oral
      antibiotics as compared to preoperative oral antibiotics alone.

      SECONDARY OBJECTIVES:

      I. To determine rates of post-operative clostridium difficile infection, adynamic ileus,
      cardiopulmonary complications, urinary tract infection, length of stay and mortality in
      patients given preoperative oral antibiotics with a mechanical bowel prep versus preoperative
      antibiotics alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak</measure>
    <time_frame>Up to 30 days post operation</time_frame>
    <description>The difference in incidence of SSI (antibiotics [ABX] - ABX + prep) will be calculated with an upper 95% confidence bound. Exploratory analysis will consider stratum specific estimates of differences in subgroups defined by BMI and diabetes status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative clostridium difficile infection</measure>
    <time_frame>Up to 30 days post operation</time_frame>
    <description>The difference in incidence of SSI (ABX - ABX + prep) will be calculated with an upper 95% confidence bound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adynamic ileus</measure>
    <time_frame>Up to 30 days post operation</time_frame>
    <description>The difference in incidence of SSI (ABX - ABX + prep) will be calculated with an upper 95% confidence bound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiopulmonary complications</measure>
    <time_frame>Up to 30 days post operation</time_frame>
    <description>The difference in incidence of SSI (ABX - ABX + prep) will be calculated with an upper 95% confidence bound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urinary tract infection</measure>
    <time_frame>Up to 30 days post operation</time_frame>
    <description>The difference in incidence of SSI (ABX - ABX + prep) will be calculated with an upper 95% confidence bound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Up to 30 days post operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>Up to 30 days post operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Diverticulitis</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Arm I (mechanical bowel prep, oral antibiotics)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (oral antibiotics)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (mechanical bowel prep, oral antibiotics)</arm_group_label>
    <other_name>25322-68-3</other_name>
    <other_name>57859</other_name>
    <other_name>Ethanol</other_name>
    <other_name>Glycol</other_name>
    <other_name>Polyethylene Glycol 400</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neomycin</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (mechanical bowel prep, oral antibiotics)</arm_group_label>
    <arm_group_label>Arm II (oral antibiotics)</arm_group_label>
    <other_name>1404-04-2</other_name>
    <other_name>Neomycin Complex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (mechanical bowel prep, oral antibiotics)</arm_group_label>
    <arm_group_label>Arm II (oral antibiotics)</arm_group_label>
    <other_name>69198-10-3</other_name>
    <other_name>Flagyl</other_name>
    <other_name>Metro I.V.</other_name>
    <other_name>Satric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo colorectal resection</description>
    <arm_group_label>Arm I (mechanical bowel prep, oral antibiotics)</arm_group_label>
    <arm_group_label>Arm II (oral antibiotics)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing ileocolic resections, partial and total colectomies, and rectal
             resections for neoplasm, inflammatory bowel disease, or diverticulitis

          -  Subjects with the mental capacity to give informed consent

        Exclusion Criteria:

          -  Patients undergoing emergent colorectal resections

          -  Patients who are decisionally-impaired and lack the mental capacity to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Phillips, MD</last_name>
    <phone>(215) 551-0360</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Phillips, MD</last_name>
      <phone>215-551-0360</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org</url>
    <description>Sidney Kimmel Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Diverticulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Neomycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

